@article{aa0eaa89eead4b6b8bc6cab54a180f77,
title = "Reply to Verweij et al. [6]",
author = "Greene, \{Reginald E.\} and Schlamm, \{Haran T.\} and Oestmann, \{J{\"o}rg W.\} and Paul Stark and Christine Durand and Olivier Lortholary and Wingard, \{John R.\} and Raoul Herbrecht and Patricia Ribaud and Patterson, \{Thomas F.\} and Troke, \{Peter F.\} and Denning, \{David W.\} and Bennett, \{John E.\} and \{De Pauw\}, \{Ben E.\} and Rubin, \{Robert H.\}",
note = "Funding Information: ceived honoraria from Pfizer and Schering-Plough. H.T.S. and P.F.T. are employees of Pfizer. O.L. has served on the speakers{\textquoteright} bureaus of Pfizer, Merck, and Astellas. J.R.W. has served as a consultant and advisor for Pfizer, Merck, Schering-Plough, and Nektar; has received honoraria from Pfizer and Merck; and has received research funding from Pfizer. R.H. has served as a consultant and advisor for Pfizer, Merck, Gilead, and Schering-Plough and has received research funding from Pfizer. P.R. has received honoraria from Pfizer, Merck, and Schering-Plough. T.F.P. has served as a consultant and advisor for Pfizer, Schering-Plough, Astellas, Merck, Affinium, Basilea, Diversa, Eisai, J Uriach, MediciNova, Microbia, Nektar, Rib-X, and Human Genome Sciences; has been on the speakers{\textquoteright} bureau for Pfizer, Schering-Plough, Astellas, and Merck; and has received research funding from Schering-Plough, Astellas, Merck, Enzon, and Pfizer. D.W.D. has received research funding from Pfizer. B.E.dP. has received honoraria from Pfizer and Merck. R.H.R. has served as a consultant and advisor for and has received honoraria from Pfizer and Merck. H.T.S. is a shareholder in Pfizer. J.E.B. is a shareholder in Merck. All other authors: no conflicts Funding Information: Potential conflicts of interest. P.E.V. has received research funding from Pfizer, Gilead Sciences, Merck, Basilea, and Schering-Plough; has been a consultant for Pfizer and Schering-Plough; and has served on the speakers{\textquoteright} bureau for Merck and Schering-Plough. J.P.D. has received research funding from AM-Phama VA and Schering-Plough; has been a consultant for Janssen Pharmaceuticals, Gilead Sciences, and Pfizer; and has served on the speakers{\textquoteright} bureau for Janssen Pharmaceuticals, Gilead Sciences, and Pfizer. L.V.D.: no conflicts.",
year = "2007",
month = jun,
day = "15",
doi = "10.1086/518388",
language = "English (US)",
volume = "44",
pages = "1667--1668",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "12",
}